An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals

Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Offersgaard, Anna, Duarte Hernandez, Carlos Rene, Feng, Shan, Marichal-Gallardo, Pavel, Holmbeck, Kenn, Pihl, Anne Finne, Fernandez-Antunez, Carlota, Alzua, Garazi Peña, Hartmann, Katrine Top, Pham, Long V., Zhou, Yuyong, Gammeltoft, Karen Anbro, Fahnøe, Ulrik, Schneider, Uffe Vest, Pedersen, Gabriel Kristian, Jensen, Henrik Elvang, Christensen, Jan Pravsgaard, Ramirez, Santseharay, Bukh, Jens, Gottwein, Judith Margarete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829433/
https://www.ncbi.nlm.nih.gov/pubmed/36644321
http://dx.doi.org/10.1016/j.isci.2023.105949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829433/
https://www.ncbi.nlm.nih.gov/pubmed/36644321
http://dx.doi.org/10.1016/j.isci.2023.105949

Ejemplares similares